편두통 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측(2018-2028년) : 치료제별, 투여 경로별, 유통 경로별, 지역별, 경쟁

The Migraine Therapeutics Market, valued at USD 3.76 Billion in 2022, is poised for robust growth in the forecast period, with an anticipated Compound Annual Growth Rate (CAGR) of 4.45% through 2028.

This market is experiencing remarkable growth, driven by a combination of factors that include the increasing prevalence of patients with migraine, advancements in pharmaceutical research, and the expansion of treatment options. Migraine, a debilitating neurological disorder, afflicts millions of individuals worldwide, leading to substantial demand for effective therapeutics. The market is witnessing a shift towards more targeted and personalized treatment approaches, with the emergence of novel migraine-specific drugs and biologics. Additionally, the growing awareness of migraine's socio-economic impact has prompted governments and healthcare organizations to invest in research and development, further fueling market expansion.

Pharmaceutical companies are heavily involved in research and development efforts to introduce innovative therapies, including calcitonin gene-related peptide (CGRP) inhibitors and gepants, which have shown promising results in alleviating migraine symptoms. These novel therapies are anticipated to gain significant market traction, potentially replacing traditional medications and opening up new revenue streams for manufacturers.

Furthermore, advancements in drug delivery systems, such as wearable devices and nasal sprays, are enhancing patient convenience and compliance, which will drive market growth. Additionally, the adoption of telemedicine and telehealth platforms for migraine management is on the rise, offering patients easier access to healthcare professionals and further boosting market prospects.

Key Market Drivers

High Prevalence of Migraine

The high prevalence of migraine is a pivotal factor driving the growth of the Migraine Therapeutics Market. Migraine is a widespread neurological disorder that affects a substantial portion of the global population. Its prevalence is a testament to the urgent need for effective therapeutic solutions, creating a vast and enduring market demand.

Migraine is not a condition limited by age, gender, or demographic factors, making it an inclusive healthcare concern. It affects individuals across various age groups, including children, adults, and the elderly, thus expanding the potential patient pool for migraine therapeutics. This broad demographic reach underlines the market's resilience and long-term growth prospects.

The economic implications of migraine cannot be overstated. This condition often leads to significant disability, absenteeism from work, and diminished productivity, resulting in substantial socioeconomic burdens. As a result, governments, healthcare providers, and pharmaceutical companies are increasingly recognizing the urgency of addressing migraine. This recognition has translated into increased investments in research, development, and treatment options, further bolstering the market.

The Migraine Therapeutics Market thrives on innovation and the quest for novel, more effective treatments. The growing awareness of migraine's impact on individuals' quality of life has led to greater patient engagement and demand for improved therapeutic options. Consequently, pharmaceutical companies are continually exploring innovative drug candidates, such as calcitonin gene-related peptide (CGRP) inhibitors and gepants, to provide better relief to migraine sufferers.

Advancements in Genomic Research

Advancements in genomic research have emerged as a pivotal catalyst in shaping the landscape of the Migraine Therapeutics Market. The integration of genomics into the field of migraine treatment has brought about a profound shift toward precision medicine and personalized therapeutics.

Genomic research has facilitated the identification of specific genetic markers and variations associated with migraine susceptibility and severity. This newfound understanding has paved the way for the development of highly targeted and effective therapeutic interventions, marking a significant departure from the one-size-fits-all approach that characterized migraine treatment in the past.

One of the most remarkable contributions of genomic research to the Migraine Therapeutics Market is the discovery of genetic mutations related to migraine, including those associated with ion channels and neurotransmitter pathways. These discoveries have unlocked novel drug targets and paved the way for the development of precision medications tailored to individuals' genetic profiles.

Furthermore, genomics has enabled the identification of patient subgroups within the migraine population. By categorizing patients based on their genetic predispositions and molecular pathways involved in their migraine attacks, pharmaceutical companies can design clinical trials with greater specificity, ensuring that new therapeutics are tested on the most relevant patient cohorts. This not only enhances the chances of successful drug development but also expedites regulatory approvals, thereby accelerating the market entry of innovative migraine treatments.

In the business context, these advancements in genomic research have introduced a competitive edge to pharmaceutical companies engaged in migraine therapeutics. Companies that invest in genomic research and develop precision medicines stand to gain a significant market advantage by offering tailored solutions that promise higher efficacy and fewer side effects, ultimately leading to increased market share and revenue.

Key Market Challenges

Drug Development Complexity

The Drug Development Complexity is a substantial challenge in the Migraine Therapeutics Market. Developing effective migraine treatments demands a nuanced understanding of the complex pathophysiology of the condition, making it a formidable obstacle for pharmaceutical companies.

Migraine is not a one-size-fits-all disorder; it manifests differently in patients and has various triggers and symptom profiles. This inherent variability poses a significant hurdle in drug development. Identifying the right molecular targets and mechanisms to address this heterogeneity requires extensive research and clinical validation.

Moreover, the neurological intricacies involved in migraine are still not fully understood, making the drug discovery process particularly challenging. Researchers must delve into the intricate interplay of neurotransmitters, receptors, and genetic factors that contribute to migraine onset and progression.

Conducting clinical trials for migraine therapeutics can also be a time-consuming and costly endeavor. Large patient cohorts and long observation periods are often required to assess the safety and efficacy of potential treatments. Patient recruitment and retention can be arduous, and the outcomes are influenced by factors such as placebo effects and the subjective nature of pain reporting.

Regulatory agencies like the FDA maintain strict standards for drug approval, demanding robust clinical data to demonstrate safety and efficacy. Meeting these stringent criteria, especially in a field as intricate as migraine, adds another layer of complexity.

Furthermore, as the understanding of migraine evolves, so do the endpoints and measures used in clinical trials, necessitating constant adaptation and refinement of research methodologies.

Regulatory Hurdles

Regulatory hurdles constitute a formidable challenge in the Migraine Therapeutics Market, significantly impacting the development and commercialization of new migraine treatments. These hurdles arise from the rigorous and exacting standards set by regulatory agencies like the FDA, which are designed to ensure the safety and efficacy of pharmaceutical products.

One of the primary regulatory challenges is the time-consuming and resource-intensive process of obtaining regulatory approval. Developing a new migraine therapeutic involves extensive pre-clinical research and multiple phases of clinical trials, each of which requires meticulous planning, execution, and documentation. Delays at any stage can prolong the time to market, increasing development costs and potentially allowing competitors to gain a competitive edge.

Furthermore, regulatory agencies demand robust and comprehensive data to support the safety and efficacy of a new migraine treatment. This necessitates large-scale clinical trials involving diverse patient populations, often spanning several years. Meeting these evidentiary requirements can be both financially burdensome and time-consuming.

The regulatory landscape for migraine therapeutics is also dynamic, with evolving guidelines and standards. Keeping abreast of these changes and ensuring that clinical trial designs align with current expectations is a constant challenge for pharmaceutical companies.

In addition, regulatory hurdles extend to post-approval monitoring and compliance, where manufacturers must continue to demonstrate product safety and efficacy while addressing any emerging safety concerns promptly.

The complexity of the regulatory process can vary by region, as different countries have their own regulatory authorities and requirements. This can further complicate market entry and commercialization efforts, requiring companies to navigate a complex web of regulations and standards.

Key Market Trends

Precision Medicine

Precision medicine is a pivotal trend revolutionizing the Migraine Therapeutics Market. It represents a paradigm shift in healthcare, wherein treatments are tailored to the unique genetic, molecular, and clinical characteristics of individual patients. This approach acknowledges the inherent variability in migraine presentations and responses to treatment, providing a more targeted and effective way to manage the condition.

In the context of the Migraine Therapeutics Market, precision medicine involves identifying specific genetic markers, molecular pathways, and biomarkers associated with migraine susceptibility, triggers, and severity. Through advanced genetic testing and molecular profiling, healthcare providers and pharmaceutical companies can gain insights into a patient's migraine profile, enabling the development of personalized therapeutic strategies.

For pharmaceutical companies, precision medicine offers a competitive advantage by allowing them to design and test treatments that are more likely to succeed. Instead of relying on a one-size-fits-all approach, drug development efforts can be directed toward specific patient subgroups with shared genetic characteristics. This not only enhances the chances of clinical trial success but also expedites the regulatory approval process, potentially accelerating the time to market for innovative migraine therapeutics.

From a business perspective, precision medicine can lead to improved patient outcomes and greater market acceptance. Patients who receive treatments tailored to their genetic and molecular profiles are more likely to experience relief from their migraine symptoms, resulting in higher patient satisfaction and loyalty. Moreover, pharmaceutical companies that invest in precision medicine can differentiate themselves in the competitive Migraine Therapeutics Market, potentially commanding premium prices for personalized treatments.

CGRP Inhibitors

Calcitonin gene-related peptide (CGRP) inhibitors have emerged as a transformative trend in the Migraine Therapeutics Market. These novel pharmaceuticals target a key molecule, CGRP, involved in migraine pathophysiology, and have demonstrated remarkable efficacy in preventing and treating migraine attacks. In the business landscape of migraine therapeutics, CGRP inhibitors have had a profound impact.

Firstly, CGRP inhibitors have significantly expanded the treatment options available to migraine patients. They represent a class of drugs specifically designed to address the underlying causes of migraine, providing a more targeted and effective approach to management. This has resulted in increased patient demand for these medications, leading to substantial market growth.

Furthermore, the introduction of CGRP inhibitors has changed the competitive dynamics of the Migraine Therapeutics Market. Pharmaceutical companies have invested heavily in the development of these drugs to gain a competitive edge. As a result, there is heightened competition in the market, which can lead to price competition and innovative marketing strategies to capture market share.

CGRP inhibitors have also influenced the regulatory landscape. The successful approval and adoption of these drugs have set a precedent for the approval of other novel migraine therapies, encouraging further research and development in the field. However, regulatory agencies continue to scrutinize these drugs' long-term safety profiles, necessitating ongoing monitoring and potential modifications.

From a business perspective, CGRP inhibitors have offered pharmaceutical companies a lucrative market opportunity. These drugs command premium prices due to their effectiveness, and their widespread adoption has contributed to revenue growth in the Migraine Therapeutics Market. Additionally, ongoing research into combination therapies and alternative delivery methods for CGRP inhibitors presents further business opportunities for innovation and market expansion.

Segmental Insights

Therapeutics Insights

The Pain-Relieving Segment dominates the Migraine Therapeutics market and is predicted to continue expanding over the coming years. Firstly, pain relief is the most immediate and pressing concern for migraine sufferers. Migraine attacks are characterized by severe and debilitating headaches, often accompanied by symptoms like nausea, vomiting, and light sensitivity. As a result, individuals seek immediate relief from the excruciating pain, making pain-relieving medications a critical component of their migraine management. Secondly, pain-relieving medications have a well-established presence in the market. Over the counter (OTC) pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, have long been the go-to options for many migraine patients. These medications are easily accessible, cost-effective, and widely recognized for their pain-alleviating properties. Thirdly, the pain-relieving segment includes prescription medications specifically formulated for migraines, such as triptans. These drugs offer targeted relief by constricting blood vessels and blocking pain pathways. Their effectiveness in managing migraine symptoms has made them a staple in migraine treatment, further solidifying the dominance of the pain-relieving segment. Moreover, the pain-relieving segment continues to evolve with ongoing research and development efforts. Pharmaceutical companies are constantly innovating to enhance the efficacy, safety, and convenience of pain-relieving migraine therapeutics, ensuring that these medications remain at the forefront of migraine management.

Regional Insights

The North America region has established itself as the leader in the Migraine Therapeutics Market in 2022. Firstly, North America benefits from a robust healthcare infrastructure and a well-developed pharmaceutical industry. This infrastructure supports extensive research and development efforts, making it conducive to innovation in migraine therapeutics. Pharmaceutical companies in the region have been at the forefront of developing novel drugs, including CGRP inhibitors, which have gained significant market share due to their effectiveness in managing migraines. Secondly, North America has a high prevalence of migraine patients. The region's population, lifestyle factors, and genetic predisposition contribute to a substantial patient pool seeking migraine treatments. This large and growing market demand has encouraged pharmaceutical companies to invest heavily in research and development to cater to the needs of these patients. Additionally, North America has a sophisticated healthcare system with well-established regulatory processes. The Food and Drug Administration (FDA) in the United States, for example, has stringent but transparent guidelines for drug approval. The successful approval of migraine-specific drugs and therapies in North America has instilled confidence in both healthcare providers and patients, driving market growth. Furthermore, the region has witnessed increased awareness about the socioeconomic impact of migraine. This awareness has led to greater public and private investments in migraine research and treatment, further cementing North America's position as a leader in the Migraine Therapeutics Market.

Key Market Players

• Amgen Inc.

• Teva Pharmaceutical Industries Limited

• GlaxoSmithKline LLC

• Eli Lilly and Company

• Bausch Health Cos Inc

• Novartis AG

• AbbVie Inc

• Lundbeck Inc

• Reddy's Laboratories Limited

• Impel Pharmaceuticals Inc

Report Scope:

In this report, the Migraine Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Migraine Therapeutics Market, Therapeutics:

• Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others)
• Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)

Migraine Therapeutics Market, Route of Administration:

• Oral & Nasal
• Injectables

Migraine Therapeutics Market, Distribution Channel:

• Retail Pharmacy
• Hospital Pharmacy
• Others

Migraine Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• Italy
• France
• Spain
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Migraine Therapeutics Market.

Available Customizations:

• Migraine Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

• 4.1. Ongoing Clinical Trials
• 4.2. Completed Clinical Trials
• 4.3. Terminated Clinical Trials
• 4.4. Breakdown of Pipeline, By Development Phase
• 4.5. Breakdown of Pipeline, By Status
• 4.6. Breakdown of Pipeline, By Therapeutic Area
• 4.7. Breakdown of Pipeline. By Region
• 4.8. Clinical Trials Heat Map

5. Voice of Customer

6. Global Migraine Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutics {Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others), and Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)}
  • 6.2.2. By Route of Administration (Oral & Nasal v/s Injectables)
  • 6.2.3. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others)
  • 6.2.4. By Region
  • 6.2.5. By Company (2022)
• 6.3. Market Map

7. North America Migraine Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutics
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Migraine Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutics
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Canada Migraine Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutics
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Mexico Migraine Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutics
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel

8. Europe Migraine Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutics
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. Germany Migraine Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutics
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. United Kingdom Migraine Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutics
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Italy Migraine Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecasty
      • 8.3.3.2.1. By Therapeutics
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. France Migraine Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutics
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Spain Migraine Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutics
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Migraine Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutics
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Migraine Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutics
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. India Migraine Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutics
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Japan Migraine Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutics
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel
  • 9.3.4. South Korea Migraine Therapeutics Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Therapeutics
      • 9.3.4.2.2. By Route of Administration
      • 9.3.4.2.3. By Distribution Channel
  • 9.3.5. Australia Migraine Therapeutics Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Therapeutics
      • 9.3.5.2.2. By Route of Administration
      • 9.3.5.2.3. By Distribution Channel

10. South America Migraine Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutics
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Migraine Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutics
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Argentina Migraine Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutics
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Colombia Migraine Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutics
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Migraine Therapeutics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Therapeutics
  • 11.2.2. By Route of Administration
  • 11.2.3. By Distribution Channel
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Migraine Therapeutics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Therapeutics
      • 11.3.1.2.2. By Route of Administration
      • 11.3.1.2.3. By Distribution Channel
  • 11.3.2. Saudi Arabia Migraine Therapeutics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Therapeutics
      • 11.3.2.2.2. By Route of Administration
      • 11.3.2.2.3. By Distribution Channel
  • 11.3.3. UAE Migraine Therapeutics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Therapeutics
      • 11.3.3.2.2. By Route of Administration
      • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Development
• 13.2. Mergers & Acquisitions

14. Global Migraine Therapeutics Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Treatment Types

16. Competitive Landscape

• 16.1. Business Overview
• 16.2. Service Offerings
• 16.3. Recent Developments
• 16.4. Key Personnel
• 16.5. SWOT Analysis
  • 16.5.1. Amgen Inc.
  • 16.5.2. Teva Pharmaceutical Industries Limited
  • 16.5.3. GlaxoSmithKline LLC
  • 16.5.4. Eli Lilly and Company
  • 16.5.5. Bausch Health Cos Inc
  • 16.5.6. Novartis AG
  • 16.5.7. AbbVie Inc
  • 16.5.8. Lundbeck Inc
  • 16.5.9. Reddy's Laboratories Limited
  • 16.5.10. Impel Pharmaceuticals Inc

17. Strategic Recommendations

18. About Us & Disclaimer